Hepatic amyloidosis (Primary [AL], immunoglobulin light chain): The natural history in 80 patients

Morie Gertz, Robert A. Kyle

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Purpose: We wished to study patients with a premortem diagnosis of primary hepatic amyloidosis to determine what clinical and laboratory features might assist in recognizing the disease and assessing prognosis. Patients and methods: A group of 80 patients with liver biopsy proven primary hepatic amyloidosis was followed from diagnosis to death. Results: At presentation, 77 percent of the group had an associated nephrotic syndrome, congestive heart failure, peripheral neuropathy, or orthostatic hypotension. Certain clues suggested the diagnosis of hepatic amyloidosis in patients with liver disease, including the following: (1) proteinuria (88 percent); (2) abnormal serum protein electrophoresis (monoclonal protein or hypogammaglobulinemia, 64 percent); (3) hyposplenism on the peripheral blood smear (62 percent), defined by the presence of Howell-Jolly bodies; and (4) hepatomegaly disproportional to the liver enzyme abnormalities. Liver function tests were not sensitive or specific. Hepatomegaly from amyloid was frequently seen, with normal levels of alkaline phosphatase, aspartate aminotransferase, and bilirubin (32 percent). Myeloma was diagnosed in 11 patients but had no effect on the clinical course. In vitro coagulation abnormalities were common, bleeding was infrequent, and liver biopsy carried a slightly increased risk. The median survival of the entire group was nine months, and projected five- and 10-year survival rates were 13 and 1 percent, respectively. Conclusion: Because survival is poor and no clinical features permit prospective recognition of those patients in whom the disease is likely to have an indolent course, a trial of therapy is warranted in all patients.

Original languageEnglish (US)
Pages (from-to)73-80
Number of pages8
JournalThe American journal of medicine
Volume85
Issue number1 C
DOIs
StatePublished - Jan 1 1988

Fingerprint

Immunoglobulin Light Chains
Natural History
Liver
Hepatomegaly
Erythrocyte Inclusions
Biopsy
Agammaglobulinemia
Orthostatic Hypotension
Survival
Liver Function Tests
Nephrotic Syndrome
Peripheral Nervous System Diseases
Amyloidosis
Aspartate Aminotransferases
Primary amyloidosis
Proteinuria
Bilirubin
Amyloid
Alkaline Phosphatase
Electrophoresis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hepatic amyloidosis (Primary [AL], immunoglobulin light chain) : The natural history in 80 patients. / Gertz, Morie; Kyle, Robert A.

In: The American journal of medicine, Vol. 85, No. 1 C, 01.01.1988, p. 73-80.

Research output: Contribution to journalArticle

@article{d6db6472c78748d2aca02c2ec7c67b28,
title = "Hepatic amyloidosis (Primary [AL], immunoglobulin light chain): The natural history in 80 patients",
abstract = "Purpose: We wished to study patients with a premortem diagnosis of primary hepatic amyloidosis to determine what clinical and laboratory features might assist in recognizing the disease and assessing prognosis. Patients and methods: A group of 80 patients with liver biopsy proven primary hepatic amyloidosis was followed from diagnosis to death. Results: At presentation, 77 percent of the group had an associated nephrotic syndrome, congestive heart failure, peripheral neuropathy, or orthostatic hypotension. Certain clues suggested the diagnosis of hepatic amyloidosis in patients with liver disease, including the following: (1) proteinuria (88 percent); (2) abnormal serum protein electrophoresis (monoclonal protein or hypogammaglobulinemia, 64 percent); (3) hyposplenism on the peripheral blood smear (62 percent), defined by the presence of Howell-Jolly bodies; and (4) hepatomegaly disproportional to the liver enzyme abnormalities. Liver function tests were not sensitive or specific. Hepatomegaly from amyloid was frequently seen, with normal levels of alkaline phosphatase, aspartate aminotransferase, and bilirubin (32 percent). Myeloma was diagnosed in 11 patients but had no effect on the clinical course. In vitro coagulation abnormalities were common, bleeding was infrequent, and liver biopsy carried a slightly increased risk. The median survival of the entire group was nine months, and projected five- and 10-year survival rates were 13 and 1 percent, respectively. Conclusion: Because survival is poor and no clinical features permit prospective recognition of those patients in whom the disease is likely to have an indolent course, a trial of therapy is warranted in all patients.",
author = "Morie Gertz and Kyle, {Robert A.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1016/0002-9343(88)90505-0",
language = "English (US)",
volume = "85",
pages = "73--80",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "1 C",

}

TY - JOUR

T1 - Hepatic amyloidosis (Primary [AL], immunoglobulin light chain)

T2 - The natural history in 80 patients

AU - Gertz, Morie

AU - Kyle, Robert A.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Purpose: We wished to study patients with a premortem diagnosis of primary hepatic amyloidosis to determine what clinical and laboratory features might assist in recognizing the disease and assessing prognosis. Patients and methods: A group of 80 patients with liver biopsy proven primary hepatic amyloidosis was followed from diagnosis to death. Results: At presentation, 77 percent of the group had an associated nephrotic syndrome, congestive heart failure, peripheral neuropathy, or orthostatic hypotension. Certain clues suggested the diagnosis of hepatic amyloidosis in patients with liver disease, including the following: (1) proteinuria (88 percent); (2) abnormal serum protein electrophoresis (monoclonal protein or hypogammaglobulinemia, 64 percent); (3) hyposplenism on the peripheral blood smear (62 percent), defined by the presence of Howell-Jolly bodies; and (4) hepatomegaly disproportional to the liver enzyme abnormalities. Liver function tests were not sensitive or specific. Hepatomegaly from amyloid was frequently seen, with normal levels of alkaline phosphatase, aspartate aminotransferase, and bilirubin (32 percent). Myeloma was diagnosed in 11 patients but had no effect on the clinical course. In vitro coagulation abnormalities were common, bleeding was infrequent, and liver biopsy carried a slightly increased risk. The median survival of the entire group was nine months, and projected five- and 10-year survival rates were 13 and 1 percent, respectively. Conclusion: Because survival is poor and no clinical features permit prospective recognition of those patients in whom the disease is likely to have an indolent course, a trial of therapy is warranted in all patients.

AB - Purpose: We wished to study patients with a premortem diagnosis of primary hepatic amyloidosis to determine what clinical and laboratory features might assist in recognizing the disease and assessing prognosis. Patients and methods: A group of 80 patients with liver biopsy proven primary hepatic amyloidosis was followed from diagnosis to death. Results: At presentation, 77 percent of the group had an associated nephrotic syndrome, congestive heart failure, peripheral neuropathy, or orthostatic hypotension. Certain clues suggested the diagnosis of hepatic amyloidosis in patients with liver disease, including the following: (1) proteinuria (88 percent); (2) abnormal serum protein electrophoresis (monoclonal protein or hypogammaglobulinemia, 64 percent); (3) hyposplenism on the peripheral blood smear (62 percent), defined by the presence of Howell-Jolly bodies; and (4) hepatomegaly disproportional to the liver enzyme abnormalities. Liver function tests were not sensitive or specific. Hepatomegaly from amyloid was frequently seen, with normal levels of alkaline phosphatase, aspartate aminotransferase, and bilirubin (32 percent). Myeloma was diagnosed in 11 patients but had no effect on the clinical course. In vitro coagulation abnormalities were common, bleeding was infrequent, and liver biopsy carried a slightly increased risk. The median survival of the entire group was nine months, and projected five- and 10-year survival rates were 13 and 1 percent, respectively. Conclusion: Because survival is poor and no clinical features permit prospective recognition of those patients in whom the disease is likely to have an indolent course, a trial of therapy is warranted in all patients.

UR - http://www.scopus.com/inward/record.url?scp=0023945210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023945210&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(88)90505-0

DO - 10.1016/0002-9343(88)90505-0

M3 - Article

C2 - 3389383

AN - SCOPUS:0023945210

VL - 85

SP - 73

EP - 80

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 1 C

ER -